Literature DB >> 10757020

Evaluation of recombinant alphaviruses as vectors in gene therapy.

J J Wahlfors1, S A Zullo, S Loimas, D M Nelson, R A Morgan.   

Abstract

Alphavirus vectors based on Sindbis virus and Semliki Forest virus (SFV) were characterized as potential gene transfer vectors. Initial studies were performed using vectors engineered to transfer either lacZ or green fluorescent protein (GFP). High levels of gene transfer were achieved in human primary fibroblasts, BHK and 293T cells, with low levels of transduction observed in more than 20 other target cells. Alphavirus-based expression was generally very high, but transient in every cell type. Replication-competent alphavirus was never detected in SFV preparations but could be produced by Sindbis-based vectors at a frequency of up to 3 x 10(-3) infectious units per ml. We constructed a human clotting factor IX (hFIX) cDNA-containing Sindbis virus and compared it with hFIX cDNA-harboring adenoviral and retroviral vectors. In most cases, hFIX levels obtained with Sindbis vector were initially at least an order of magnitude higher than those obtained with other viral vectors. These data demonstrate that alphavirus vectors compare favorably with adenovirus vectors as systems to promote high-level transient gene expression and should be considered as an alternative vector for gene transfer and potential gene therapy studies.

Entities:  

Mesh:

Year:  2000        PMID: 10757020     DOI: 10.1038/sj.gt.3301122

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  9 in total

1.  Corpus callosum: a favorable target for rSFV-mediated gene transfer to rat brain with broad and efficient expression.

Authors:  Zhao-Jian Li; Peng Sun; Hong-Di Zhang; Shi-Fang Li; Xia Liu; Ren-Zhi Wang
Journal:  J Mol Neurosci       Date:  2010-05-12       Impact factor: 3.444

2.  Comparative protein profiling of B16 mouse melanoma cells susceptible and non-susceptible to alphavirus infection: Effect of the tumor microenvironment.

Authors:  Jelena Vasilevska; Gustavo Antonio De Souza; Maria Stensland; Dace Skrastina; Dmitry Zhulenvovs; Raimonds Paplausks; Baiba Kurena; Tatjana Kozlovska; Anna Zajakina
Journal:  Cancer Biol Ther       Date:  2016-09-16       Impact factor: 4.742

3.  Viral mutagenesis as a means for generating novel proteins.

Authors:  John N Davis; Anthony N van den Pol
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

4.  A novel neurotropic expression vector based on the avirulent A7(74) strain of Semliki Forest virus.

Authors:  Markus J V Vähä-Koskela; Minna T Tuittila; Petra T Nygårdas; Jonas K-E Nyman; Markus U Ehrengruber; Martin Renggli; Ari E Hinkkanen
Journal:  J Neurovirol       Date:  2003-02       Impact factor: 2.643

5.  In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins.

Authors:  Yubin Kang; Colleen S Stein; Jason A Heth; Patrick L Sinn; Andrea K Penisten; Patrick D Staber; Kenneth L Ratliff; Hong Shen; Carrie K Barker; Inês Martins; C Matthew Sharkey; David Avram Sanders; Paul B McCray; Beverly L Davidson
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

Review 6.  Context-aware synthetic biology by controller design: Engineering the mammalian cell.

Authors:  Nika Shakiba; Ross D Jones; Ron Weiss; Domitilla Del Vecchio
Journal:  Cell Syst       Date:  2021-06-16       Impact factor: 11.091

7.  Differential In Vitro Infection of Neural Cells by Astroviruses.

Authors:  Andrew B Janowski; Robyn S Klein; David Wang
Journal:  mBio       Date:  2019-07-09       Impact factor: 7.867

8.  Rescue of Infectious Sindbis Virus by Yeast Spheroplast-Mammalian Cell Fusion.

Authors:  Lin Ding; David M Brown; John I Glass
Journal:  Viruses       Date:  2021-04-01       Impact factor: 5.048

Review 9.  Cytoplasmic RNA viruses as potential vehicles for the delivery of therapeutic small RNAs.

Authors:  Jose A Usme-Ciro; Natalia Campillo-Pedroza; Fernando Almazán; Juan C Gallego-Gomez
Journal:  Virol J       Date:  2013-06-07       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.